MedTrace Logo

Osimertinib In EGFR Mutant Lung Cancer

NCT03586453 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-29

No results posted yet for this study

Summary

This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.

The names of the study drug involved in this study is:

\- Osimertinib (Tagrisso)

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Osimertinib

Patients who fulfill eligibility criteria will be entered into the trial to receive Osimertinib. After the screening procedures confirm participation in the research study: * Osimertinib: Oral, Daily 28 day cycle. * Radiographic assessment: every 2 cycles for first 6 months and then every 3 cycles until disease progression. * Tumor biopsy between C4 and C8 and at disease progression

Sponsors & Collaborators

Principal Investigators

  • Pasi A Jänne, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-13
Primary Completion
2028-02-28
Completion
2028-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03586453 on ClinicalTrials.gov